coumarin has been researched along with Liver Dysfunction in 10 studies
2H-chromen-2-one: coumarin derivative
| Excerpt | Relevance | Reference |
|---|---|---|
| "No evidence was obtained that the studied polymorphism in CYP2A6 is a determinant of the coumarin-associated liver dysfunction." | 9.10 | Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. ( Burian, M; Freudenstein, J; Henneicke-von Zepelin, HH; Legrum, W; Naser-Hijazi, B; Tegtmeier, M, 2003) |
| "Coumarin is an effective pharmacological treatment, but is banned in some countries due to incidences of hepatotoxicity in rats and mice, and the rare finding of similar hepatotoxicity in humans." | 6.44 | CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? ( Farinola, N; Piller, NB, 2007) |
| "No evidence was obtained that the studied polymorphism in CYP2A6 is a determinant of the coumarin-associated liver dysfunction." | 5.10 | Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. ( Burian, M; Freudenstein, J; Henneicke-von Zepelin, HH; Legrum, W; Naser-Hijazi, B; Tegtmeier, M, 2003) |
| "The administration of single doses of coumarin to the rat was found to produce hepatic centrilobular necrosis and also to depress a number of hepatic enzyme activities within 24 h." | 3.67 | Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat. ( Lake, BG, 1984) |
| "Coumarin is an effective pharmacological treatment, but is banned in some countries due to incidences of hepatotoxicity in rats and mice, and the rare finding of similar hepatotoxicity in humans." | 2.44 | CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? ( Farinola, N; Piller, NB, 2007) |
| " Coumarin is less toxic in the baboon, gerbil and certain strains of mice, which resemble man in their extensive formation of the 7-hydroxy metabolite." | 2.38 | Species differences in the metabolism and hepatotoxicity of coumarin. ( Fentem, JH; Fry, JR, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burian, M | 1 |
| Freudenstein, J | 1 |
| Tegtmeier, M | 1 |
| Naser-Hijazi, B | 1 |
| Henneicke-von Zepelin, HH | 1 |
| Legrum, W | 1 |
| DE NICOLA, P | 1 |
| DONALD, AC | 1 |
| HUNTER, RB | 1 |
| TUDHOPE, GR | 1 |
| WALKER, W | 1 |
| WHITTON, I | 1 |
| FERGUSON, JH | 2 |
| FRESH, JW | 2 |
| LEWIS, JH | 2 |
| SPAUGH, E | 2 |
| ZUCKER, MB | 2 |
| Farinola, N | 1 |
| Piller, NB | 1 |
| Colebunders, R | 1 |
| Schutyser, G | 1 |
| De Schepper, A | 1 |
| Verselder, R | 1 |
| Lake, BG | 1 |
| Bader, R | 1 |
| Mannucci, PM | 1 |
| Tripodi, A | 1 |
| Hirsh, J | 1 |
| Keller, F | 1 |
| Solleder, EM | 1 |
| Hawkins, P | 1 |
| Peng, M | 1 |
| Pelzer, H | 1 |
| Teijidor, LM | 1 |
| Fentem, JH | 1 |
| Fry, JR | 1 |
| Pelkonen, O | 1 |
| Rautio, A | 1 |
| Raunio, H | 1 |
| Mäenpää, J | 1 |
| Hakkola, J | 1 |
3 reviews available for coumarin and Liver Dysfunction
| Article | Year |
|---|---|
CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?
Topics: Animals; Chemical and Drug Induced Liver Injury; Coumarins; Humans; Liver Diseases; Lymphedema; Phar | 2007 |
Species differences in the metabolism and hepatotoxicity of coumarin.
Topics: Animals; Chemical and Drug Induced Liver Injury; Coumarins; Humans; In Vitro Techniques; Liver Disea | 1993 |
Regulation of coumarin 7-hydroxylation in man.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2A6; Cytochrome P-450 Enzyme | 1994 |
1 trial available for coumarin and Liver Dysfunction
| Article | Year |
|---|---|
Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.
Topics: Adult; Aged; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; | 2003 |
6 other studies available for coumarin and Liver Dysfunction
| Article | Year |
|---|---|
[Clinical significance of factor VII].
Topics: Blood Coagulation; Coumarins; Factor VII; Hemostatics; Heparin Antagonists; Humans; Infant, Newborn; | 1953 |
Prothrombin and haemorrhage.
Topics: Blood Coagulation; Coumarins; Hemorrhage; Hemostatics; Humans; Liver Diseases; Prothrombin; Prothrom | 1954 |
Acquired hypoprothrombinemia.
Topics: Coumarins; Hemorrhagic Disorders; Humans; Hypoprothrombinemias; Infant; Infant, Newborn; Infant, New | 1957 |
Acquired hypoprothrombinemia.
Topics: Coumarins; Hemorrhagic Disorders; Humans; Hypoprothrombinemias; Infant; Infant, Newborn; Infant, New | 1957 |
Acquired hypoprothrombinemia.
Topics: Coumarins; Hemorrhagic Disorders; Humans; Hypoprothrombinemias; Infant; Infant, Newborn; Infant, New | 1957 |
Acquired hypoprothrombinemia.
Topics: Coumarins; Hemorrhagic Disorders; Humans; Hypoprothrombinemias; Infant; Infant, Newborn; Infant, New | 1957 |
Hepatic haematoma, a complication during anticoagulant therapy. A case report.
Topics: Chemical and Drug Induced Liver Injury; Coumarins; Female; Hematoma; Humans; Liver; Liver Diseases; | 1984 |
Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat.
Topics: Acetylcysteine; Animals; Chemical and Drug Induced Liver Injury; Coumarins; Kinetics; Liver; Liver D | 1984 |
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids.
Topics: Animals; Brain Chemistry; Calibration; Coumarins; Evaluation Studies as Topic; Female; Heparin; Huma | 1994 |